Cosmo Bio Company,Limited (3386.T)
JPY 1169.0
(0.6%)
JPY 1169.0
(0.6%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 669 Million JPY | -23.41% |
| 2022 | 958 Million JPY | -24.35% |
| 2021 | 1.21 Billion JPY | 27.01% |
| 2020 | 928 Million JPY | 62.48% |
| 2019 | 613 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 295 Million JPY | 197.98% |
| 2024 Q2 | 50 Million JPY | -87.46% |
| 2023 Q1 | 410 Million JPY | 167.97% |
| 2023 Q3 | -7 Million JPY | -108.33% |
| 2023 FY | - JPY | -23.41% |
| 2023 Q4 | 98 Million JPY | 1500.0% |
| 2023 Q2 | 84 Million JPY | -79.51% |
| 2022 Q3 | 112 Million JPY | 0.0% |
| 2022 FY | - JPY | -24.35% |
| 2022 Q4 | 153 Million JPY | 36.61% |
| 2021 FY | - JPY | 27.01% |
| 2020 FY | - JPY | 62.48% |
| 2019 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Shin Nippon Biomedical Laboratories, Ltd. | 8.98 Billion JPY | 92.551% |
| DNA Chip Research Inc. | -217 Million JPY | 408.295% |
| H.U. Group Holdings, Inc. | 13.64 Billion JPY | 95.098% |
| FALCO HOLDINGS Co., Ltd. | 3.13 Billion JPY | 78.64% |
| BML, Inc. | 16.41 Billion JPY | 95.925% |
| Human Metabolome Technologies, Inc. | 306.48 Million JPY | -118.282% |
| Precision System Science Co., Ltd. | -661.75 Million JPY | 201.096% |